Introduction
Prostate cancer (PCa) is the second leading cause of male cancer mortality in the US (Jemal et al., 2007) . Development, progression and maintenance of disease are dependent on the action of the androgen receptor (AR), a ligand activated transcription factor. On ligand (testosterone or 5-a-dihydrotestosterone, DHT) binding, AR is released from inhibitory heat-shock proteins, translocates to the nucleus, and binds to DNA at androgen response elements within the regulatory regions of target genes (Feldman and Feldman, 2001 ). Therein, AR induces a program of gene transcription that results in diverse activities dependent on cellular context (Burnstein, 2005; Pienta and Bradley, 2006; Shand and Gelmann, 2006; Balk and Knudsen, 2008) . Prostate specific antigen (PSA) is the best characterized AR target gene whose expression is utilized as a biomarker for disease progression (Lilja et al., 2008) . Proliferation of PCa cells require a functional AR; therefore, first line treatment for disseminated disease targets the AR pathway (Salesi et al., 2005) . Advanced PCa is treated with hormone therapy (Sharifi et al., 2005) as accomplished by: (1) pharmacological or surgical blockade of androgen production (androgen ablation), (2) use of direct AR antagonists that compete for DHT binding (Petrylak, 2005) and induce corepressor recruitment (Hadaschik and Gleave, 2007) or (3) a combination of both regimens (combined androgen blockade). These therapies all impinge on the AR carboxy-terminal ligand-binding domain (LBD) as a mechanism to ablate AR action. The validity of AR as an appropriate biochemical target is apparent, as these regimens initiate cell cycle arrest and/or cell death in vivo, resulting in tumor regression (Agus et al., 1999) . These outcomes are almost invariably accompanied by concomitant PSA reduction (Lilja et al., 2008) , indicating that AR can be effectively inhibited through carboxy-terminal directed therapies. Unfortunately, relapse occurs within a median time of 24-36 months (Feldman and Feldman, 2001 ). This 'castration-resistant' phenotype represents an incurable stage of disease (Petrylak, 2005; Hadaschik and Gleave, 2007) , and there is a significant need to develop new modes of therapeutic intervention to treat castration-resistant PCa (CRPC; Petrylak, 2005) . Remarkably, it is evident that these androgen-independent tumors typically arise as a result of restored AR activity (Feldman and Feldman, 2001; Burnstein, 2005; Pienta and Bradley, 2006) , as noted by the observations that visible tumor recurrence is almost always preceded by rising PSA, and that AR is active in CRPC (Lilja et al., 2008) . Mechanisms that restore AR activity include gain-of-function mutations, AR amplification, ligand-independent AR activation, deregulation of AR cofactors, and intracrine androgen production (Feldman and Feldman, 2001; Stanbrough et al., 2006; Chmelar et al., 2007; Locke et al., 2008; Montgomery et al., 2008) . Thus, targeting the AR in CRPC remains a major goal of current investigations.
Mechanisms that control AR-dependent cell cycle progression are increasingly well understood (Balk and Knudsen, 2008) . In part, androgen-dependent activation of mTOR induces translation of cyclin D1 (Xu et al., 2006) , which can bind to cyclin-dependent kinase 4 (CDK4) to initiate cell cycle progression (Matsushime et al., 1992; Quelle et al., 1993; Knudsen et al., 1998) . However, only a subset of cyclin D1 is typically associated with CDK4 (James et al., 2008) , and cyclin D1 has multiple CDK4-independent functions that control transcription factor action (Ewen et al., 1993; Skapek et al., 1995; Cheng et al., 1998; Ganter et al., 1998; Inoue and Sherr, 1998; Kato et al., 1998; Parry et al., 1999; Bienvenu et al., 2001; Coqueret, 2002; Ewen and Lamb, 2004; Fu et al., 2004) . In prostatic cells, accumulated cyclin D1 binds directly to the AR Nterminal domain and inhibits ligand-dependent AR activity through well-defined mechanisms (Knudsen et al., 1999; Reutens et al., 2001; Petre et al., 2002; Burd et al., 2005) . First, cyclin D1 binds to the AR FxxLF motif and therein prevents the formation of conformational changes (intramolecular N/C interactions; Burd et al., 2005) required for AR stabilization on chromatin (Wong et al., 1993) . Second, the ability of cyclin D1 to bind histone deacetylase 3 is required for AR inhibition (Li et al., 2002; Lin et al., 2002; Petre et al., 2002) . These activities of cyclin D1 map to a repressor domain (RD) within the protein which is distinct from the CDK4-regulatory motif (PetreDraviam et al., 2005) . Thus, it was hypothesized that segregation of the cyclin D1 functional domains may provide a means to develop new strategies in targeting AR activity in PCa.
Herein, the discrete influence of cyclin D1 RD function was assessed in androgen-dependent PCa and CRPC cells. This study demonstrates that RD is sufficient to suppress ligand-dependent AR transcriptional activity. In AR-positive, androgen-dependent PCa cells, RD inhibited cell cycle progression and induced cell death. By contrast, no cytostatic or cytotoxic effects were observed in AR-negative PCa cells or in tested AR-positive cells of other lineages. RD also elicited cell death in a subset of CRPC cells, dependent on Akt status. Lastly, RD sensitized cells to the therapeutic AR antagonist bicalutamide (Casodex).
Combined, these studies demonstrate that the AR-inhibitory motif of cyclin D1 is sufficient to prevent AR activity, specifically inhibit PCa cell growth, and enhance the efficacy of existing therapeutics. These studies provide the impetus for the development of RD mimetics for targeted therapeutic intervention.
Results
Cyclin D1 repressor domain inhibits AR transcriptional activity in vitro The region of cyclin D1 required for AR association and repression (RD) has been previously described ( Figure 1a , left panel; Petre-Draviam et al., 2005) . To segregate this activity away from the cell cycle regulatory functions of cyclin D1, RD was fused to an epitope (either green fluorescent protein (GFP), or 3 Â Flag), and expression validated after transient transfection into LNCaP (AR-positive, androgen-dependent) PCa cells. As shown, the peptide of expected molecular weight (Flag-RD: 18 kDa) was detected. H2B-GFP was used as a control for transfection efficiency (Figure 1a , right panel).
Although RD is required for cyclin D1-mediated suppression of AR activity (Petre-Draviam et al., 2005) , sufficiency of this domain to inhibit AR had not been determined. To test this, transient transfection assays were performed wherein CV1 cells (spontaneously immortalized epithelial cells lacking endogenous AR; Rundlett et al., 1990) were cotransfected in the absence of hormone with plasmids encoding empty vector, wildtype cyclin D1, an RD-deficient mutant (cyclin D1-DRD) or RD alone (Flag-RD) and the ARR2-Luc reporter, pSG5-AR and cytomegalovirus (CMV)-bgalactosidase (as an internal transfection control). Following transfection, cells were stimulated with 1 nM DHT or 0.1% ethanol (vehicle control), and relative luciferase activity determined. As shown in Figure 1b , cyclin D1 inhibited the ligand-dependent transactivation function of AR by 56%, whereas cyclin D1-DRD had no significant effect. These findings are consistent with previous reports wherein RD was required for cyclin D1-mediated AR inhibition (Petre-Draviam et al., 2005) . Additionally, RD expression significantly reduced AR activity (40% suppression), demonstrating for the first time that RD is sufficient to inhibit AR function in transient transfection assays.
To validate these observations using endogenous AR target genes, LNCaP cells were infected in the presence of androgen with an adenovirus encoding GFP, wildtype cyclin D1 (positive control), or GFP-RD. As shown, full-length cyclin D1 reduced endogenous PSA expression by 61% relative to the GFP control (set to 1), whereas RD inhibited PSA mRNA production by 32% (Figure 2a) . A second AR target gene of clinical importance, TMPRSS2 (Perner et al., 2007; Tomlins et al., 2007; Mehra et al., 2007a, b) , was analysed to determine the specificity of RD-mediated inhibition. Similar to PSA, both cyclin D1 and RD reduced TMPRSS2 mRNA production (by 68 and 55%, respectively; Figure 2b ). There was no detectable change in AR protein levels between mock, GFP or RD infected cells (Figure 2c ), indicating that the observed changes in transcriptional regulation are not due to a reduction in AR levels. Together, these data demonstrate that RD is sufficient to reduce AR transcriptional regulation of clinically relevant AR target genes.
RD inhibits cell cycle progression in AR-positive PCa cells As PCa cell proliferation is dependent on AR, the capacity of RD to block cell cycle progression was determined after transient transfection. As shown, neither full-length cyclin D1 nor RD impacted S-phase progression in CV1 (AR-negative) cells, compared to control (Figure 3a) . Validation of RD expression is provided in the lower panel, with GFP provided as a control for transfection efficiency. By contrast, RD inhibited cell cycle progression in a dose-dependent manner in LNCaP (Figure 3b) , with full-length cyclin D1 as positive control and cyclin D1-DRD as negative control. These data demonstrate that in PCa cells dependent on AR for cell cycle progression, RD is sufficient to inhibit S-phase progression. To determine if the effect of RD is reliant on functional AR in the context of PCa, AR-negative, androgen-independent PC3 cells (Kaighn et al., 1979) were analysed in parallel. Similar to the results observed with CV1 cells, neither cyclin D1 nor derivatives thereof induced a detectable effect on cell cycle progression (Figure 3c ), further suggesting that the cell cycle inhibitory function of RD is dependent on AR. Taken together, these data demonstrate that RD of cyclin D1 is sufficient to selectively attenuate cell cycle progression in AR-positive PCa cells. After transfection, cells were treated with 1 nM 5-a-dihydrotestosterone (DHT) or 0.1% ethanol vehicle, and relative luciferase activity determined. Normalized AR activity in the presence of ligand was set to 100 with the average fold induction by DHT presented. Error bars represent standard deviation. Statistical analyses were performed using ANOVA followed by a Newman-Kuels multiple comparison post test. ***Po0.001 Data shown reflects at least nine independent data points.
were performed to assess relative expression of GFP-RD and GFP (bottom panels). As shown, in Figure 4a . Specificity was addressed using AR-negative PC3 cells, wherein there was no change in cell cycle distribution, sub-G 1 (o2 N) accumulation, or PARP cleavage were detected (Figure 4d) . Similarly, whereas GFP-RD accumulation was readily observed in CV1 (4E), MCF7 (AR-positive breast cancer; Birrell et al., 1995; 4F) or PC12(Q10) (rat pheochromocytoma with tet-inducible human AR) cells (Walcott and Merry, 2002; 4G) , no PARP cleavage was detected (left panels). In sum, these data demonstrate that RD-induced cell death appears specific to AR-positive, androgen-dependent PCa. Given the disparity in CRPC response, the underlying mechanisms were investigated. It is known that AR in C4-2 is more stable when compared to the parental line (LNCaP; Gregory et al., 2001) , but alteration in AR levels are unlikely to underlie the observed resistance to RD-induced cell death, as further elevation in RD expression failed to alter cellular outcome (data not shown). By contrast, it is known that although LNCaP cells lack functional phosphatase and tensin homolog (PTEN) and therefore harbor activated Akt (Davies et al., 1999) , the C4-2 derivative exhibits a marked enhancement of Akt activity as compared to the parental cell line (Ghosh et al., 2005) . This observation was confirmed in this study wherein the ratio of phosphorylated (active) Akt to total Akt was significantly higher in C4-2 versus parental LNCaP (Figure 5d , compare lanes 1 and 2). Given the importance of Akt in modulating cell survival, its role in resistance to RD-mediated cell death was challenged by pretreatment of C4-2 cells with the PI3K inhibitor LY294002. LY294002 pretreatment alone resulted in modest PARP cleavage (Figure 5e , lane 1), consistent with previous reports that this compound can elicit moderate cell death (Gottschalk et al., 2005) . Importantly, LY294002-treated cells were sensitized to RDinduced PARP cleavage (Figure 5e (data not shown). Combined, these data indicate that whereas RD can induce a cytostatic response in all AR-positive PCa cells tested, the cytotoxic effects of RD in CRPC are sensitive to PI3K/Akt activation status.
RD enhances the effect of currently used AR targeted therapies As RD induced both cytostatic and cytotoxic response, the potential of RD as a novel adjuvant therapeutic was assessed in combination with androgen ablation or AR antagonists. After androgen withdrawal in LNCaP cells, bromodeoxyuridine (BrdU) incorporation was minimal (Figure 6a , left striped bar), verifying the reliance of these cells on androgen for cellular proliferation. Earlier introduction of RD further reduced S-phase progression (Figure 6a ), thus indicating that RD can cooperate with androgen-ablative strategies. To determine the effect of RD in combination with bicalutamide, experiments were performed in parallel using cells cultured in the presence of androgen. As expected, bicalutamide alone reduced BrdU incorporation by 52% (Figure 6b bars; Maucher and von Angerer, 1993) , and RD alone significantly reduced BrdU incorporation by 37% (Figure 6b , left black bar), in the presence of androgen. Cooperative effects were observed when these treatments were combined (26% of control). Further studies were performed to assess dose response, wherein it was observed that RD sensitized cells to low dose bicalutimide (Figure 6c ). Taken together, these data demonstrate that RD acts to enhance the cellular response to existing hormone therapy regimens.
Discussion
It has previously been established that cyclin D1 modulates nuclear receptor function independent of its cell cycle regulatory role. Here, we show that the transcriptional corepressor activity can be segregated from the cyclin regulatory region, and that this motif (RD) is sufficient to suppress AR activity. Decreased AR activity was observed in both transient assays and through analysis of endogenous AR target gene expression. Consistent with the observation that AR activity is required for PCa cell growth, RD inhibited PCa cell proliferation in vitro in AR-positive cells, and surprisingly induced death in cells that retain androgen dependence. In CRPC, it was revealed that the cytotoxic response is sensitive to PI3K/Akt status. No effect was seen in AR-negative PCa cells, or nonprostatic cells which harbor AR, thus showing specificity. Lastly, RD sensitized cells to the inhibitory action of clinically relevant AR antagonists (bicalutamide) to induce a significant decrease in cell cycling. These data suggest that mimetics of RD function could serve as a novel PCa therapeutic and/or be of benefit in combination with current therapeutic regimens. Functional motifs of cyclin D1 that are needed for cell cycle and CDK4 regulation have been well defined (Coqueret, 2002; Knudsen, 2006) and remarkably, these functions appear to be distinct from the region of cyclin D1 that exerts transcriptional repression (Knudsen et al., 1999; Lin et al., 2002; Wang et al., 2003; Fu et al., 2005) . The present data demonstrate for the first time that the RD motif is sufficient to impede AR activity and induce cell cycle arrest and/or cell death, thus indicating that CDK regulation is not required for this function. Not all transcriptional regulatory actions of cyclin D1 occur through this motif. For example, the ability of cyclin D1 to modulate the estrogen receptor occurs through the nuclear receptor interaction motif (LxxLL, aa 254-259; Neuman et al., 1997; Zwijsen et al., 1998) , which is dispensable for AR regulation (Petre et al., 2002) . By contrast, transcriptional repression of AR, peroxisome proliferator-activated receptors-g (PPARg) and dentin matrix protein-1 (DMP1) requires the RD (Inoue and Sherr, 1998; Fu et al., 2005; PetreDraviam et al., 2005) . This domain is known to associate with histone deacetylases, and indeed, cyclin D1-mediated suppression of AR (Petre et al., 2002) , PPARg (Li et al., 2002) , and TR can be partially reversed by HDAC inhibitors. A secondary function of RD is manifest through interaction of RD with the AR FxxLF domain, causing blockade of ligand-induced conformational changes required for transactivation. Although the present data show that RD is sufficient to inhibit AR activity and induce cell cycle arrest and/or cell death, it cannot be formally ruled out that selected RD effects are mediated by interaction with other transcription factors. Cellular effects do appear to require AR, as AR-independent cells are refractory to RD action. It is unlikely that PPARg plays a part, as RD refractory PC3 cells express high levels of this receptor (Subbarayan et al., 2005) . It is equally unlikely that the potential interaction between cyclin D1 and DMP1 results in the observed cellular consequence, as cyclin D1 suppresses the cell cycle inhibitory capacity of DMP1 (Inoue and Sherr, 1998) . However, TR can induce LNCaP proliferation (Esquenet et al., 1995) , and thus the contribution of TR to the observed effects could be of interest. Although future studies will likely reveal additional transcription factors that interact with RD, the present data are strongly suggestive that AR is the critical determinant of the observed cellular response.
The demonstrated capacity of RD to inhibit AR transcriptional activity is of importance, as both early PCa and CRPC cells remain dependent on AR signaling for survival and proliferation (Burnstein, 2005) and AR knockdown inhibits growth of both PCa and CRPC cells in vivo (Cheng et al., 2006) . Herein, RD not only impinged on AR transcriptional activity and inhibited proliferation of AR-positive PCa cells, but also induced cell death, dependent on PI3K/Akt status. It is well established that Akt is a prosurvival factor (Franke et al., 1997) , and PTEN inactivation (upstream negative regulator of PI3K/Akt) has been implicated in the transition to CRPC (Shen and Abate-Shen, 2007) . Loss of PTEN is a frequent event in PCa, and has been correlated with poor prognosis (McMenamin et al., 1999) . The present observation that CRPC with Akt hyperactivity acquire resistance to the cytotoxic effects of RD is of translational importance, and provides the foundation for future studies aimed at coordinated targeting of AR N/C interaction and Akt inhibition.
Previous studies using 'decoy' peptides derived from the AR N-terminus resulted in phenotypes of some similarity to RD. These decoy peptides (encoding aa 1-558 of AR), acting in part by blocking N to C interaction, suppressed cell cycle progression of ARpositive, androgen-dependent cells in vitro (Minamiguchi et al., 2004) and in vivo, and an increase in apoptotic cell death was observed (Quayle et al., 2007a, b) . Thus, the ability of peptides that bind the AR N-terminus to induce cell death is not without precedent. As observed in unbiased analysis (CES Comstock et al., in preparation), only a subset of AR target genes are affected by cyclin D1, and interrogation of these should provide clues as to the basis of cell death. Additionally, recently published microarray data demonstrate that D-type cyclins exert distinct transcriptional regulation in liver (Mullany et al., 2008) , suggesting that the effects of RD of cyclin D1 are likely different than those of RD of cyclin D3. Lastly, it was previously demonstrated that cells lacking cyclin D1 have increased mitochondrial size and function (Wang et al., 2006) , thus leading to the as-of-yet unchallenged possibility that these cyclin D1 actions may in part underlie the effects seen in androgen-dependent PCa cells.
As specific induction of tumor cell death is the ultimate goal of cancer therapy, it will be critical to discern the mechanism by which RD elicits the cytotoxic response.
As current therapies for disseminated PCa are only transiently effective, determining means by which to improve on current treatment strategies is of paramount importance. As shown, RD enhanced the cytostatic response to androgen withdrawal, but was more effective as a cooperating factor for bicalutamide. This disparity in the magnitude of cooperation is not unexpected, as AR is deprived of ligand under conditions of androgen ablation, and cyclin D1 impinges predominantly on ligand-bound AR. However, bicalutamide acts through competing for binding to the AR LBD, and induces corepressor recruitment (Zhu et al., 2006) . Thus, the capacity of RD to interact with the AR N-terminal FxxLF motif and thereby block the N to C terminal interactions likely underlies its ability to enhance the action of bicalutamide. Thus, these studies provide proof of principle evidence that simultaneous targeting of multiple AR functional domains may have therapeutic benefit. As this study indicates that mimetics of RD action could be of therapeutic benefit, the concept of rational drug design must be addressed. Important precedent exists in the design of imatinib (Sharifi and Steinman, 2002) , and nutlins (Hu et al., 2007) . A significant hurdle with regard to RD as a therapeutic includes the lack of a crystal structure for the cyclin D1 protein (or domains thereof). RD is proposed to form a five a-helix structure (Petre-Draviam et al., 2005) ; importantly, this domain is conserved in cyclin D3 (Olshavsky et al., 2007) , which also retains the ability to bind AR and block N to C interaction, but harbors distinct transcriptional modulatory activities. Future development of structural investigations will assist in the long-term goal of generating RD mimetics.
In summary, the studies herein demonstrate that the RD motif induced AR-specific effects in PCa cells, is sufficient to inhibit AR activity, which results in both cytostatic and cytotoxic responses. The capacity of RD to cooperate with and enhance the efficacy of a currently utilized AR antagonist further advocates the importance of the findings, and provide evidence that concurrent targeting of both N and C terminal AR functions may be of clinical benefit. Future studies will determine if this small peptide can be translated into a clinically relevant treatment for PCa.
Materials and methods
Cell culture and treatment LNCaP, C4-2, CV1, MCF7, 22Rv1, PC3 and PC12(Q10) cells were cultured as previously described (Petre et al., 2002; Walcott and Merry, 2002; Petre-Draviam et al., 2003) . For steroid-free conditions, charcoal-dextran-treated FBS (CDT; Hyclone Laboratories, Logan, UT, USA) was utilized. LY290042 was obtained from Calbiochem (San Diego, CA, USA), and used at 3.125 mM.
Transfection and transcription assays CV1 cells were transfected as previously described (Chen and Okayama, 1987; Knudsen et al., 1999) . Following transfection, cells were treated with either 1 nM DHT or 0.1% ethanol vehicle. Relative luciferase activity was assessed using the Promega (Madison, WI, USA) luciferase assay kit and Galacto-Star reagent (Applied Biosystems, Foster City, CA, USA) was used to detect b-galactosidase activity (transfection normalization).
Expression vectors
Most plasmids were previously described (Petre et al., 2002; Petre-Draviam et al., 2003 . RD-Flag construct was generated by removing RD from the GST-RD construct (Petre-Draviam et al., 2005) via BamH1 digestion. The insert was then ligated into the BamHI site of the pcDNA-Flag plasmid and screened for orientation. Adenoviral GFP-RD was generated utilizing the AD-Easy system (Qbiogene, Irvine, CA, USA). Briefly, GFP-RD (Petre-Draviam et al., 2005) was excised with NheI and XbaI and inserted into the XbaI site of pShuttle-CMV. After recombination with Ad-easy1, adenovirus was generated and purified as per manufacturer's protocol.
Immunoblot analysis SDS-polyacrylamide gel electrophoresis was performed as previously described (Knudsen et al., 1998) , and immunoblotting achieved using antisera against GFP (sc-9996), FLAG (sc-7787), AR (sc-816), Lamin B (sc-6217), PARP (Cell Signaling, Beverly, MA, USA; 9542), phosphorylated Akt (Cell Signaling; 193H12), total Akt (Cell Signaling; 9272), cdk4 (sc-601) or b-tubulin (sc-5274). Signal was visualized using either the Odyssey IR Imaging System (LI-COR Biosciences, Lincoln, NE, USA) or chemiluminescence (Perkin Elmer, Boston, MA, USA).
Cell proliferation assays
To monitor BrdU incorporation, cells were cultured on cover slips and transfected with H 2 B-GFP (transfection marker) and one of vector (pCDNA3.1), cyclin D1, DRD or RD-Flag. BrdU staining and counting was performed as described (Knudsen et al., 1998; Petre-Draviam et al., 2005) . For growth assays, indicated cells were seeded into poly-L-lysine-coated six-well dishes (except for PC3 cells, which are strongly adherent), infected after 24 h with virus encoding either GFP or RD-GFP, and cell number counted using trypan blue exclusion and a hemocytometer. Total cell number was determined from at least three independent experiments each with three biological replicates per time point. For flow cytometry, parallel studies using these conditions were used, but at 96 h postinfection, cells were fixed in ethanol, stained with propidium iodide (0.2 mg/ml) and subjected to flow cytometry. Samples were quantified on a BD FACS-Calibur using BD CellQuestPro software (BD Biosciences, San Jose, CA, USA), and analysed using FlowJo software (Tree Star Inc.).
Reverse transcriptase PCR LNCaP cells were seeded on poly-L-lysine-coated 6 cm dishes, infected 24 h later, and the media was replaced 24 h postinfection. RNA was harvested 48 h postinfection using Trizol reagent (Life Technologies, Gaithersburg, MD, USA) as per the manufacturer's protocols. Amplification of TMPRSS2, glyceraldehyde-3-phosphate dehydrogenase and PSA was performed as previously described HessWilson et al., 2006) .
